ARDS - Aridis brokers agreement with Kermode for zoonotic viruses shares surge 9%

Microcap Aridis Pharmaceuticals, Inc. (ARDS) has entered into an outlicensing and product discovery agreement with privately held Kermode Biotechnologies, Inc. for vaccines and monoclonal antibodies (mAbs) that could be used for the treatment of zoonotic viruses.Zoonotic viruses are those found in animals that, like SARS-CoV-2, the virus the causes COVID-19, have the ability to also infect humans.Under the terms of the agreement, Aridis will grant a non-exclusive license to Kermode allowing it to use Aridis' APEX monoclonal antibody pathogen discovery platform to discover vaccines and mAbs for African Swine Fever Virus, with an option for swine influenza virus.Aridis retains rights to any products for human uses discovered in the collaboration, while Kermode retain rights to mAbs and vaccines discovered for veterinary uses.Aridis shares are up 9.4% to $6.06 in premarket trading.

For further details see:

Aridis brokers agreement with Kermode for zoonotic viruses, shares surge 9%